Pegylated Interferon Lambda for Covid-19
New England Journal of Medicine, 2023 Mingqiang, Wang +2 more
openaire +4 more sources
Gastroenterology Research and Practice, 2016 Aim. To evaluate the compliance and virological response to pegylated interferon alpha 2a treatment of chronic hepatitis B in Roma population compared to majority Caucasian population in Slovakia. Methods. Retrospective evaluation of a cohort of all Roma
Sylvia Drazilova +7 more
doaj +1 more source
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. [PDF]
, 2020 Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open-label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged ...
Balistreri, William F +20 more
core
Eradicating chronic Hepatitis C Viraemia : lessons learnt during the last decade [PDF]
, 2005 Over the last decade a better understanding of the mechanism for immune disposal of hepatocytes infected with the Hepatitis C virus enabled the design of antiviral regimens with increasing efficacy.
Pullicino, Edgar
core
Pegylated and Conventional Interferon-α Induce Comparable Transcriptional Responses and Inhibition of Tumor Growth in a Human Melanoma SCID Mouse Xenotransplantation Model [PDF]
, 2004 Clemens Krepler +5 more
openalex +1 more source
Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis. [PDF]
, 2009 BACKGROUND/AIMS: Efficacy of retreatment with pegylated interferon (PEG-IFN) plus ribavirin of non-responders to standard or pegylated IFN plus ribavirin has been assessed in various studies, but sustained virologic response (SVR) rates are variable and ...
Andriulli, A. +7 more
core
Diagnosis and treatment of viral liver fibrosis
The Saudi Journal of Gastroenterology, 2005 This review summarized the diagnostic value of fibrosis biomarkers and the efficacy of anti-viral treatments on fibrosis progression. Non-invasive biomarkers can facilitate the screening and management of chronic hepatitis C and B.
Poynard Thierry +3 more
doaj
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG) [PDF]
, 2017 Background: Combination of temozolomide (TMZ) with nonpegylated interferon alfa is associated with increased efficacy in terms of response rates compared with monotherapy.
Becker, J. C. +14 more
core
Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients [PDF]
, 2006 Gloria Taliani +19 more
openalex +1 more source